ORI Capital
Venture capitalHong Kong · Pre-Seed–Late Stage · 15 people tracked
Find your way into ORI Capital
1,885 people in our graph share verified history with the ORI Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
ORI Capital backs innovative early-stage biotech companies on a global basis. Its funds focus on diagnostics, drug delivery, and therapeutics, targeting the disease areas responsible for the highest mortality rates, including cancer, cardiovascular disease, and neurodegenerative disease. The firm combines scientific insight with a mission to develop treatments that save lives, drawing on a mix of artificial and human intelligence in its investment approach.
Source: firm website, verified Aug 3, 2026.
Team · 15 people
from the firm's website & public directories
What they invest in
from 2 of 5 portfolio companiesBiotech ×2Healthtech ×2Medical Devices ×2Deep Tech ×1
HQs:United Kingdom×1United States×1
Investments · 5 tracked
founders shown can be your intro path
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG Crossover+2 more
Natick, US
Gang Song(Executive Officer, Director)Moonsoo Jin(Executive Officer, Director)Hong Fang Song(Director)
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology FundAgent CapitalBaillie Gifford+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
<UNKNOWN>Semma Therapeutics
Exits · 1
1 IPOsCG OncologyNASDAQ: CGON
Portfolio news
latest coverage across their companies
Orchard Therapeutics · x.com · Aug 8, 2026
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| CG Oncology | 4.8% | $28.00 | Dec 2024 | $100.5M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has ORI Capital made?
- ORI Capital has 5 tracked investments, 1 of which have exited.
- What stage does ORI Capital invest at?
- ORI Capital invests at the Pre-Seed, Seed, Series A, Series B, Late Stage stages.
- What sectors does ORI Capital focus on?
- ORI Capital focuses on AI & Machine Learning, Biotech, Healthtech, Impact & Social Good, Medical Devices.
- Where is ORI Capital located?
- ORI Capital is headquartered in Hong Kong, HK.
Similar investors
Artesian is a venture capital manager offering Venture Capital as a Service (VCaaS): building and operating dedicated sole-LP venture funds and related infrastructure for institutions such as governments, corporations, industry bodies, universities, superannuation funds and family offices.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Muirwoods Ventures is a venture capital firm investing in healthcare, technology, mobility, and the environment, with an emphasis on sustainability and mass-market solutions.